Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has received a consensus rating of “Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $34.38.

Several equities research analysts recently weighed in on the stock. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and increased their target price for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Finally, Wells Fargo & Company cut their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. increased its position in shares of Xencor by 147.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock worth $62,748,000 after purchasing an additional 1,858,440 shares in the last quarter. RTW Investments LP grew its position in shares of Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock worth $55,218,000 after buying an additional 1,827,883 shares during the period. BVF Inc. IL raised its stake in shares of Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock worth $52,596,000 after buying an additional 1,438,760 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in Xencor by 452.4% in the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock valued at $19,236,000 after buying an additional 685,557 shares during the period. Finally, Finepoint Capital LP bought a new position in Xencor in the fourth quarter valued at approximately $15,167,000.

Xencor Stock Down 1.9 %

Shares of XNCR stock opened at $12.95 on Tuesday. Xencor has a 12 month low of $12.54 and a 12 month high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $912.48 million, a PE ratio of -4.05 and a beta of 0.74. The stock has a 50 day moving average of $16.22 and a 200-day moving average of $20.30.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, equities analysts predict that Xencor will post -3.68 EPS for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.